Novartis antifungals
This article was originally published in The Tan Sheet
Executive Summary
Soltec Research grants exclusive global license for Liquipatch topical drug delivery technology to Novartis for all antifungal applications, Soltec parent Connetics announces April 8. Novartis previously licensed the technology only for use in its Lamisil line. In addition to paying Soltec an undisclosed sum to expand the license, Novartis will continue to pay product development costs, licensing fees, sales royalties and milestone payments. Liquipatch applies to skin "like a conventional topical gel and dries to form a thin, invisible, water-resistant film," Connetics says...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.